伊库利珠单抗
重症肌无力
医学
儿科
免疫学
抗体
补体系统
作者
James F. Howard,Dubravka Dodig,Lida Zeinali,Samir Macwan,Ashley Yegin,Michael Pulley,Ema Rodrigues,Pushpa Narayanaswami
标识
DOI:10.1016/j.jns.2025.123628
摘要
In routine clinical practice, eculizumab was well tolerated and effective for patients with gMG. Treatment benefits were maintained after transition to ravulizumab.
科研通智能强力驱动
Strongly Powered by AbleSci AI